| Ytd | -34.30% | |
| 1y | -2.33% |
| Open | 5.70 | Prev Close | 5.69 | Low | 5.29 | High | 5.83 | Mkt Cap | 93.80M |
| Vol | 106.38K | Avg Vol | 59.91K | EPS | -1.74 | P/E | N/A | Forward P/E | -1.19 |
| Beta | 1.46 | Short Ratio | 3.19 | Inst. Own | 15.80% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-13 | 50-d Avg | 5.52 | 200-d Avg | 6.22 | 1yr Est | 6.33 |
VRCA News
– Per-protocol interim statistical power analysis confirms no additional patients are recommended fo
Verrica Pharmaceuticals NASDAQ: VRCA reported second-quarter revenue growth in its YCANTH treatment
Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.48) per share which missed th
WEST CHESTER, Pa., July 30, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market
Under the terms of the Agreement, Verrica has granted Medomie an exclusive right to obtain and maint
WEST CHESTER, Pa., July 21, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasda
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'
- Development Partner Torii Pharmaceutical also recently announced dosing of the first Japanese pati
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq
HC Wainwright & Co. analyst Raghuram Selvaraju assumes Verrica Pharmaceuticals (NASDAQ:VRCA)
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq
Verrica Pharmaceuticals NASDAQ: VRCA reported higher first-quarter revenue and record demand for its
Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript
Verrica Pharmaceuticals Inc. (VRCA) came out with a quarterly loss of $0.41 per share versus the Zac
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.41) per share which missed th
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026,
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcino
Phase 2 Data Highlight the Observed Abscopal-like Effect of VP-315 in Non-treated Basal Cell Carcino
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing an
WEST CHESTER, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasd
WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasd
Vivani Medical (NASDAQ: VANI - Get Free Report) and Verrica Pharmaceuticals (NASDAQ: VRCA - Get Free
LOS ANGELES--(BUSINESS WIRE)---- $VRCA--VRCA Investors Have the Opportunity to Join Investigation of
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces an investiga
Verrica Pharmaceuticals (NASDAQ:VRCA) reported quarterly losses of $(0.51) per share which beat the
Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company d
